Author: Whitehawk Therapeutics

Posted Date:

May 21, 2026

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Whitehawk Therapeutics

May 21, 2026
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

Whitehawk Therapeutics

May 20, 2026
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Whitehawk Therapeutics

May 15, 2026
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing

Whitehawk Therapeutics

May 13, 2026
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Whitehawk Therapeutics

May 7, 2026
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026

Whitehawk Therapeutics

April 19, 2026
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series

Whitehawk Therapeutics

April 16, 2026
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026

Whitehawk Therapeutics

April 10, 2026
Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Whitehawk Therapeutics

March 17, 2026
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Whitehawk Therapeutics

March 12, 2026